Medicines Transparency
Alliance (MeTA): The
challenges of multi-
stakeholder working

Andrew Chetley
Communication and Cap...
Outline
   What’s an MSP?
   What’s a MeTA?
   Why is MeTA an MSP?
   What’s new in all of this?
   What has MeTA lea...
What’s an MSP?
   Multi-stakeholder process/initiative/approach
   Brings all those with an interest in or who will be
 ...
Why an MSP?
   To deal with complex issues
   Useful where there are “governance gaps”
   Where “steer and negotiate” i...
What’s a MeTA?
   International alliance: DFID, WHO, World Bank (plus 7
    pilot countries: Peru, Ghana, Uganda, Zambia,...
Source: SSDS Inc for the World Bank



Why? Complexity of
medicines supply…
                                              ...
… and more complexity
innovation                          new and
                                    different
          ...
What’s new about MeTA?
   “Learning to engage in dialogue means to
    move from hearing to listening.”




MeTA   16/09/...
Lessons
                               from MeTA

                       Right mix
                       Enough time
  ...
Challenges
      Will mutual accountability flow?
      Will civil society have a strong voice?
      Will the private ...
Will poor people in these countries
have greater access to medicines?




MeTA   16/09/2008                     11
   info@metasecretariat.org
MeTA   16/09/2008      www.MedicinesTransparency.org   12
Upcoming SlideShare
Loading in …5
×

Challenges of Multi-stakeholder processes: the experience of the Medicines Transparency Alliance

1,116 views

Published on

Outlines the main benefits and reasons for using a multistakeholder process, describes the Medicines Transparency Alliance (MeTA) and highlights key lessons and main challenges from the programme to improve access to medicines by increasing transparency and accountability in medicine supply.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,116
On SlideShare
0
From Embeds
0
Number of Embeds
5
Actions
Shares
0
Downloads
17
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Challenges of Multi-stakeholder processes: the experience of the Medicines Transparency Alliance

  1. 1. Medicines Transparency Alliance (MeTA): The challenges of multi- stakeholder working Andrew Chetley Communication and Capacity Strengthening Director International MeTA Secretariat 18 June 2009, Tracing Pharmaceuticals in South Asia: Dissemination Workshop, Edinburgh MeTA 16/09/2008 1
  2. 2. Outline  What’s an MSP?  What’s a MeTA?  Why is MeTA an MSP?  What’s new in all of this?  What has MeTA learned?  What are the big challenges?  Will this help poor people access medicines? 2 MeTA 16/09/2008
  3. 3. What’s an MSP?  Multi-stakeholder process/initiative/approach  Brings all those with an interest in or who will be affected by an issue into a new form of communication, decision finding (and maybe decision making)  3 or more stakeholder groups  Transparency, accountability, participation, equity, dialogue 3 MeTA 16/09/2008
  4. 4. Why an MSP?  To deal with complex issues  Useful where there are “governance gaps”  Where “steer and negotiate” is needed  Where movement has been bogged down  To facilitate negotiation, broaden participation, share knowledge  Correct market failures  Identify global public needs 4 MeTA 16/09/2008
  5. 5. What’s a MeTA?  International alliance: DFID, WHO, World Bank (plus 7 pilot countries: Peru, Ghana, Uganda, Zambia, Jordan, Kyrgyzstan, the Philippines)  Test the hypothesis that multi-stakeholder dialogue will develop creative solutions to problems of access to medicines  Country-led, focus on disclosure of information in 4 broad areas: Price, Quality, Availability, Promotion. 5 MeTA 16/09/2008
  6. 6. Source: SSDS Inc for the World Bank Why? Complexity of medicines supply… Constructed and produced by Steve Kinzett, JSI/Kenya - please communicate Commodity Logistics System in Kenya (as of July 2006) any inaccuracies to skinzett@cb.jsikenya.com or telephone 2727210 Commodity Type Blood Anti- Labor- Contra- Condoms MOH (colour coded) STI Vaccines Safety ceptives and for STI/ Essential Retro atory and TB/Leprosy Reagents Malaria Equip- RH HIV/AIDS Drugs Drugs Vitamin A (inc. HIV Virals ment supp- equipment prevention (ARVs) lies tests) Organization Key Government World Bank Loan Bilateral Donor Multilateral Donor NGO/Private JSI/DELIVER U U D Source of D J C G K S A Global S K N W B G funds for E F I I A N I N GOK, WB/ US Fund for A f F H GOK T UNICEF D MSF commodities I W U P I O C C D V F C D I IDA Gov AIDS, TB I D D A A V A and Malaria D A A U U K GTZ C J PSCMC Procurement E S K U N Crown W E Government Japanese (Crown Agent/Body R Private UNICEF MEDS (procurement D S A f O F Agents H M of Kenya Company implementation Agents, MSF I W P P O unit) C I GTZ, JSI A S D A and KEMSA) A KEMSA Point of first Regional KEPI Cold KEMSA Central Warehouse MEDS NPHLS store warehousing Depots Store Organization Provincial and NLTP KEMSA and KEMSA Regional Depots JSI/DELIVER/KEMSA Logistics KEPI responsible MEDS District Private for delivery to (TB/ (essential drugs, malaria drugs, Management Unit (contraceptives, (vaccines Hospital Drug (to Mission Leprosy condoms, STI kits, HIV test kits, TB and Laboratory Source district levels consumable supplies) facilities) drugs drugs, RH equipment etc) vitamin A) Staff Organization responsible for Mainly District level staff: DPHO, DPHN, DTLP, DASCO, DPHO, etc or staff from the Health Centres, delivery to sub- Dispensaries come up and collect from the District level 6 district levels
  7. 7. … and more complexity innovation new and different voices transformatio dynamic n dialogues changing business problem practice solving equity social mutual justice accountability transparency new partnerships different perspectives
  8. 8. What’s new about MeTA?  “Learning to engage in dialogue means to move from hearing to listening.” MeTA 16/09/2008 8
  9. 9. Lessons from MeTA  Right mix  Enough time  Clear aim and approach  Sufficient resources  Facilitation  Learning and flexibility MeTA 16/09/2008 9
  10. 10. Challenges  Will mutual accountability flow?  Will civil society have a strong voice?  Will the private sector engage?  Will governments let go of some control?  Is there a clear outcome, or only gradual change over time that might have happened anyway? (What can we measure?)  Can everyone win? MeTA 16/09/2008 10
  11. 11. Will poor people in these countries have greater access to medicines? MeTA 16/09/2008 11
  12. 12.  info@metasecretariat.org MeTA 16/09/2008  www.MedicinesTransparency.org 12

×